Cardiomyopathy

Hepatocyte growth factor protects injured heart muscles against further damage

Published in Gene Therapy Weekly, August 8th, 2002

by Sonia Nichols, senior medical writer - Based on an animal model study, scientists in Japan have proposed that transferring hepatocyte growth factor genes to hearts with cardiomyopathy may stimulate blood flow and confer protection against additional cardiac injury.

Cardiac fibrosis and hypertrophy are hallmarks of human primary cardiomyopathy. These events, especially fibrosis formation, are believed to stem blood flow in the heart, generating increased injury. Hepatocyte growth factor (HGF), with antifibrosis and proangiogenic properties, could be used to ameliorate myocardial disease, given the results of a study performed on Syrian hamsters with genetic...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2002-08-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry